Patent · US Active

Antitumors combinations containing antibodies recognizing specifically CD38 and bortezomib

US9314522B2 · kind B2 · utility

0Cited by
17References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 8, 2011
Grant dateApr 19, 2016
Priority date—
Expiry dateDec 23, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/24
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Pharmaceutical composition comprising an antibody specifically recognizing CD38 and bortezomib.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.